Caplin Point Laboratories has delivered robust financial performance for the quarter ended December 31, 2025, demonstrating strong growth across key metrics. The pharmaceutical company announced its Q3FY26 results with significant improvements in revenue, profitability, and operational efficiency across both emerging and regulated markets.

Strong Revenue Growth Across Segments

The company reported consolidated revenue from operations of ₹542.8 crores for Q3FY26, representing a solid 10.1% year-on-year growth compared to ₹493.0 crores in Q3FY25. Total revenue including other income reached ₹576.5 crores, up 9.9% from ₹524.3 crores in the corresponding quarter last year.

Impressive Profitability Performance

Caplin Point Laboratories reported consolidated net profit of ₹165.9 crores for Q3FY26, marking an 18.4% increase compared to ₹140.1 crores in Q3FY25. The company's EBITDA reached ₹223.4 crores, representing a substantial 15.3% year-on-year growth with EBITDA margin improving to 38.7% from 36.9% in the previous year.

Nine-Month Performance Highlights

For the nine months ended December 31, 2025, the company achieved total revenue of ₹1,674.2 crores, up 11.2% from ₹1,505.7 crores in the corresponding period last year. Nine-month net profit reached ₹476.9 crores, representing a robust 20.5% year-on-year growth. Basic earnings per share increased significantly to ₹61.98 for nine months compared to ₹51.82 in the previous year.

Strategic Business Developments

The company continues to strengthen its market position with significant developments across emerging and regulated markets. In emerging markets, Caplin Point has secured new tender orders worth $25 million in Central American markets and received approvals for 25 products in Mexico with a pipeline of 100+ products planned for filing. The company has also acquired industrial land in Mexico for establishing manufacturing and packaging facilities.

In regulated markets, Caplin Steriles Limited maintains strong performance with 55 ANDAs approved in the US. The company's US subsidiary, Caplin Steriles USA Inc, has achieved revenue of $8.7 million since inception with 29 products launched under its own label. Free cash reserves stand at ₹1,381 crores with total liquid assets of ₹2,459 crores, providing strong financial flexibility for growth initiatives.

Earnings Call Audio Recording Available

Following the announcement of Q3FY26 results, Caplin Point Laboratories has made available the audio recording of its earnings call held on February 05, 2026. The company informed both BSE Limited and National Stock Exchange of India about the availability of the earnings call recording on its official website, providing stakeholders with access to detailed discussions about the quarterly performance and strategic outlook.

Caplin Point Laboratories Limited has disclosed comprehensive voting results and scrutinizer report for the postal ballot concluded on January 31, 2026, revealing overwhelming shareholder support for the appointment of four new directors. The pharmaceutical company informed stock exchanges about the detailed voting outcomes under Regulation 44 of SEBI Listing Regulations.

Postal Ballot Process and Timeline

The postal ballot process was conducted entirely through remote e-voting, with the voting period commencing on January 2, 2026 at 9:00 AM and concluding on January 31, 2026 at 5:00 PM. The company dispatched the postal ballot notice dated December 29, 2025 via email to shareholders on December 31, 2025, with the cut-off date for voting eligibility set as December 26, 2025.

Voting Results Summary

All four resolutions received substantial shareholder approval, with voting participation reaching 78.35% of outstanding shares. The scrutinizer M. Alagar of Alagar & Associates LLP confirmed that all resolutions passed with requisite majority.

Detailed Voting Breakdown

The voting results demonstrated strong support across all shareholder categories. Promoter and Promoter Group, holding 53,642,353 shares, voted unanimously in favor of all resolutions with 100% participation. Public institutional investors, with 6,684,623 shares, showed 87.35% participation, while public non-institutional shareholders had 0.48% participation from their 15,684,720 shares.

New Board Appointments

The approved appointments include strategic leadership additions and enhanced independent oversight:

Professional Credentials

Mrs. Susan Mathew brings distinguished administrative expertise as a retired Indian Administrative Service officer with 36 years of government service. Her career included senior roles as Collector of Madras, Secretary to Government Energy Department, Chairman of Tamil Nadu Electricity Board, and Additional Chief Secretary. She holds academic credentials from Women's Christian College Chennai and was awarded the Lester Pearson Fellowship for studies at Carleton University and University of Ottawa.

Regulatory Compliance and Documentation

The company ensured full regulatory compliance with advertisements published in Financial Express (English) and Maalai Malar (Tamil) on January 1, 2026. The scrutinizer confirmed that all new directors meet regulatory requirements and are not debarred by SEBI or other authorities. Electronic voting data and records will be maintained in safe custody until the Chairman approves and signs the postal ballot minutes.